Healthcare experts have found the autoimmune disorders industry to be one of the most rapidly evolving markets. The global market for autoimmune disorder drug delivery devices is predicted to grow at a CAGR of 15.25% over the forecast period of 2020-2030. The market is driven by certain factors, including the increasing global geriatric population, increasing incidence of chronic diseases including autoimmune disorders, and rise in demand for self-injectable systems.
The market is favored by the development of autoimmune disorder drug delivery devices for several clinical areas such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, and psoriasis. The increase in the geriatric population and incurable autoimmune disorders across the globe are expected to translate into a significantly higher demand for autoimmune disorder drug delivery devices.
Furthermore, the companies are investing huge amounts in research and development of autoimmune disorder drug delivery devices. The clinical trial landscape of different autoimmune disorders has been on the rise in recent years, and this will drive the autoimmune disorder drug delivery devices market in the future.
Within the research report, the market is segmented based on indication, product type, manufacturing type, and region. Each of these segments covers the market’s snapshot over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained
View Report - https://bisresearch.com/industry-report/autoimmune-disorder-drug-delivery-devices-market.html
Market Segmentation
• Indication – Systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, and psoriasis
• Product Type – Pen injectors, auto-injectors, pre-filled syringes, and vials
• Manufacturing Type – In-house manufacturing and outsourced manufacturing
Regional Segmentation
• North America – U.S., Canada
• Europe – Germany, France, Italy, U.K., Spain, Russia, and Rest-of-Europe
• Asia-Pacific – China, Japan, India, Taiwan, South Korea, Singapore, Australia, and Rest-of-Asia-Pacific (RoAPAC)
• Latin America – Brazil, Mexico, and Rest-of-the-Latin America
• Rest-of-the-World
Growth Drivers
• Increased Prevalence of Autoimmune Disorders
• Technological Advancements in the Field of Pre-Filled Syringes
• Rising Geriatric Population
• Surge of Biosimilars and Biologics in the Pharmaceutical Market
• Device Connectivity to Ease Competitive Pressure
Market Challenges
• Strict Legal Requirements and Regulations
• Alternative Drug Delivery Technology
Market Opportunities
• Providing Injectable Drug Delivery Devices for Untapped Autoimmune Disorders
• Opportunities of Personalizing Treatments in Autoimmune Diseases
Key Companies Profiled
AbbVie Inc., Amgen Inc., F. Hoffmann- La Roche Ltd., Novartis AG, GlaxoSmithKline Plc, Bristol Myers Squibb Company, Biogen Inc., Merck KGaA, Bayer AG, Johnson & Johnson Services Inc., Teva Pharmaceutical Industries Ltd., Eli Lily and Company, Sanofi S.A., UCB Inc., and Takeda Pharmaceutical Company Limited, among others.
Request a Sample- https://bisresearch.com/requestsample?id=1010&type=download
Comments
Post a Comment